- Home
- LLY vs JNJ Comparison
LLY vs JNJ Comparison
Compare LLY & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LLY | JNJ |
|---|---|---|
| Founded | 1876 | 1886 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 979.6B | 542.4B |
| IPO Year | 2007 | 2003 |
Fundamental Metrics
Financial Performance| Metric | LLY | JNJ |
|---|---|---|
| Price | $1,215.78 | $259.60 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 20 |
| Target Price | ★ $1,218.84 | $238.20 |
| AVG Volume (30 Days) | 2.0M | ★ 7.5M |
| Earning Date | 04-30-2026 | 04-14-2026 |
| Dividend Yield | 0.81% | ★ 2.36% |
| EPS Growth | ★ 95.99 | 90.50 |
| EPS | ★ 16.19 | 4.41 |
| Revenue | ★ $65,179,000,000.00 | N/A |
| Revenue This Year | $27.15 | $6.63 |
| Revenue Next Year | $16.04 | $7.43 |
| P/E Ratio | $75.95 | ★ $59.04 |
| Revenue Growth | ★ 44.70 | N/A |
| 52 Week Low | $644.50 | $172.70 |
| 52 Week High | $1,249.45 | $274.90 |
Technical Indicators
Market Signals| Indicator | LLY | JNJ |
|---|---|---|
| Relative Strength Index (RSI) | 60.60 | 59.69 |
| Support Level | $1,107.59 | $247.97 |
| Resistance Level | $1,240.73 | $272.16 |
| Average True Range (ATR) | 36.82 | 5.42 |
| MACD | 3.93 | -0.31 |
| Stochastic Oscillator | 98.62 | 51.35 |
Price Performance
Historical ComparisonAbout LLY Eli Lilly and Company
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
About JNJ Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.